
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Results from an epidemiological study conducted byStanford University researchers provide valuable prognostic informationfor patients with mycosis fungoides.